| Literature DB >> 32002573 |
Robert W Koivula1,2, Naeimeh Atabaki-Pasdar3, Giuseppe N Giordano3, Tom White4, Jerzy Adamski5,6,7, Jimmy D Bell8, Joline Beulens9, Søren Brage4,10, Søren Brunak11,12, Federico De Masi11,12, Emmanouil T Dermitzakis13,14,15, Ian M Forgie16, Gary Frost17, Torben Hansen10,18, Tue H Hansen18, Andrew Hattersley19,20, Tarja Kokkola21, Azra Kurbasic3, Markku Laakso21, Andrea Mari22, Timothy J McDonald19, Oluf Pedersen18, Femke Rutters9, Jochen M Schwenk23, Harriet J A Teare24, E Louise Thomas8, Ana Vinuela13,14,15, Anubha Mahajan25, Mark I McCarthy26,25,27,28, Hartmut Ruetten29, Mark Walker30, Ewan Pearson16, Imre Pavo31, Paul W Franks3,26,32,33.
Abstract
AIMS/HYPOTHESIS: It is well established that physical activity, abdominal ectopic fat and glycaemic regulation are related but the underlying structure of these relationships is unclear. The previously proposed twin-cycle hypothesis (TC) provides a mechanistic basis for impairment in glycaemic control through the interactions of substrate availability, substrate metabolism and abdominal ectopic fat accumulation. Here, we hypothesise that the effect of physical activity in glucose regulation is mediated by the twin-cycle. We aimed to examine this notion in the Innovative Medicines Initiative Diabetes Research on Patient Stratification (IMI DIRECT) Consortium cohorts comprised of participants with normal or impaired glucose regulation (cohort 1: N ≤ 920) or with recently diagnosed type 2 diabetes (cohort 2: N ≤ 435).Entities:
Keywords: Beta cell function; Ectopic fat; Glycaemic control; Insulin sensitivity; Physical activity; Prediabetes; Structural equation modelling; Type 2 diabetes
Mesh:
Substances:
Year: 2020 PMID: 32002573 PMCID: PMC7054368 DOI: 10.1007/s00125-019-05083-6
Source DB: PubMed Journal: Diabetologia ISSN: 0012-186X Impact factor: 10.122
Characteristics of cohort subset used in each model
| Characteristic | Cohort 1 (no diabetes/prediabetes) | Cohort 2 (diabetes) | ||
|---|---|---|---|---|
| TC | TC-PA | TC | TC-PA | |
| Male sex, % | 83 | 83 | 57 | 60 |
| Age, years | 60.6 (6.3) | 60.6 (6.3) | 61.5 (8.3) | 61.7 (8.4) |
| BMI, kg/m2 | 27.8 (3.6) | 27.8 (3.7) | 30.5 (4.8) | 30.4 (4.6) |
| Fasting glucose, mmol/l | 5.8 (0.5) | 5.8 (0.5) | 7 (1.5) | 7 (1.4) |
| 2 h glucose, mmol/l | 6 (1.7) | 6 (1.7) | 8.6 (2.9) | 8.5 (2.8) |
| Fasting triacylglycerol, mmol/l | 1.4 (0.6) | 1.4 (0.7) | 1.5 (0.9) | 1.5 (0.9) |
| Fasting insulin, pmol/l | 73 (49) | 75 (51) | 105 (69) | 105 (68) |
| Fasting insulin secretion, pmol min−1 m−2 | 105 (40) | 106 (41) | 134 (49) | 136 (50) |
| Glucose sensitivity, pmol min−1 m−2 mmol l−1 | 107 (50) | 107 (50) | 85 (54) | 89 (56) |
| Insulin sensitivity, 2 h OGIS, ml min−1 m−2 | 374 (56) | 374 (56) | 302 (71) | 302 (70) |
| Liver fat, % | 5 (4.7) | 5 (4.7) | 8.6 (7.2) | 8.9 (7.4) |
| Pancreatic fat, % | 13.5 (9) | 13.6 (9.1) | 11.2 (7.2) | 11.7 (6.9) |
Values are mean (SD), except for male sex, which is % of subcohort
Fig. 1TC structural equation model definition diagram, fit estimates and effect estimate diagrams from a hypothesised model for the role of physical activity and liver fat in glycaemic control. (a) Model definitions, with squares representing manifest nodes and arrows indicating regression coefficients pointing towards an outcome of a respective regression. (b) Model fit; density plot of model fit χ2 from variable-randomised comparable structural equation models applied on respective dataset (10,000 iterations). Dashed vertical lines indicate TC model χ2, solid lines and shaded areas indicate χ2 of all null iterations. (c, d) Effect estimate diagrams of the defined model applied on cohort 1 (no diabetes/prediabetes, c) and cohort 2 (type 2 diabetes, d), where the arrow thickness is weighted by effect estimate magnitude, and colours red and blue indicate positive and negative estimates, respectively. All continuous variables are normally transformed and adjusted for age, sex, metformin treatment (cohort 2), study centre, total energy intake, and carbohydrate, fat and protein intake. See Text box for node and edge abbreviations
Fig. 2TC-PA structural equation model definition diagram, fit estimates and effect estimate diagrams from a hypothesised model for the role of physical activity and liver fat in glycaemic control. (a) Model definitions, with squares representing manifest nodes and arrows indicating regression coefficients pointing towards an outcome of a respective regression. (b) Model fit; density plot of model fit χ2 from variable-randomised comparable structural equation models applied on respective dataset (10,000 iterations). Dashed vertical lines indicate TC-PA model χ2, solid lines and shaded areas indicate χ2 of all null iterations. (c, d) Effect estimate diagrams of the defined model applied on cohort 1 (no diabetes/prediabetes, c) and cohort 2 (type 2 diabetes, d), where the arrow thickness is weighted by effect estimate magnitude, and colours red and blue indicate positive and negative estimates, respectively. All continuous variables are normally transformed and adjusted for: age, sex, metformin treatment (cohort 2), study centre, total energy intake, and carbohydrate, fat and protein intake. See Text box for node and edge abbreviations
Individual edge effect estimates for the TC and TC-PA structural equation models
| Outcome node/parent node (edge) | Cohort 1 | Cohort 2 (diabetes) | ||||
|---|---|---|---|---|---|---|
| β | β SE | β | β SE | |||
| TC model | ||||||
| OGIS/ | ||||||
| LF (is1) | −0.23 | 0.04 | <0.001 | −0.11 | 0.06 | 0.09 |
| LF/ | ||||||
| FI (lf1) | 0.41 | 0.04 | <0.001 | 0.44 | 0.05 | <0.001 |
| FI/ | ||||||
| FG (fi1) | −0.06 | 0.03 | 0.05 | −0.25 | 0.06 | <0.001 |
| IS (fi2) | −0.70 | 0.03 | <0.001 | −0.70 | 0.06 | <0.001 |
| FG/ | ||||||
| IS (fg1) | −0.67 | 0.03 | <0.001 | −0.73 | 0.03 | <0.001 |
| GS (fg2) | −0.26 | 0.03 | <0.001 | −0.31 | 0.03 | <0.001 |
| TG/ | ||||||
| IS (tg1) | −0.31 | 0.03 | <0.001 | −0.34 | 0.05 | <0.001 |
| LF (tg2) | 0.22 | 0.03 | <0.001 | 0.13 | 0.05 | 0.006 |
| PF/ | ||||||
| TG (pf1) | 0.14 | 0.03 | <0.001 | 0.01 | 0.05 | 0.886 |
| GS/ | ||||||
| PF (gs1) | −0.05 | 0.04 | 0.185 | <0.01 | 0.05 | 0.967 |
| IS (gs2) | −0.21 | 0.03 | <0.001 | 0.02 | 0.05 | 0.63 |
| PG/ | ||||||
| IS (pg1) | −0.58 | 0.03 | <0.001 | −0.67 | 0.03 | <0.001 |
| GS (pg2) | −0.17 | 0.03 | <0.001 | −0.38 | 0.03 | <0.001 |
| TC-PA model | ||||||
| IS/ | ||||||
| PA (is2) | 0.30 | 0.04 | <0.001 | 0.21 | 0.05 | <0.001 |
| LF (is1) | −0.20 | 0.04 | <0.001 | −0.12 | 0.07 | 0.065 |
| LF/ | ||||||
| PA (lf2) | −0.04 | 0.04 | 0.234 | −0.04 | 0.05 | 0.447 |
| FI (lf1) | 0.41 | 0.04 | <0.001 | 0.44 | 0.05 | <0.001 |
| FI/ | ||||||
| PA (fi3) | −0.12 | 0.03 | <0.001 | −0.16 | 0.05 | 0.001 |
| FG (fi1) | −0.04 | 0.03 | 0.265 | −0.23 | 0.07 | <0.001 |
| IS (fi2) | −0.64 | 0.04 | <0.001 | −0.64 | 0.07 | <0.001 |
| FG/ | ||||||
| PA (fg3) | 0.11 | 0.03 | 0.001 | 0.06 | 0.03 | 0.061 |
| IS (fg1) | −0.70 | 0.03 | <0.001 | −0.73 | 0.03 | <0.001 |
| GS (fg2) | −0.26 | 0.03 | <0.001 | −0.28 | 0.03 | <0.001 |
| TG/ | ||||||
| PA (tg3) | −0.13 | 0.04 | <0.001 | −0.13 | 0.05 | 0.012 |
| OGIS (tg1) | −0.26 | 0.04 | <0.001 | −0.30 | 0.05 | <0.001 |
| LF (tg2) | 0.22 | 0.04 | <0.001 | 0.16 | 0.05 | 0.002 |
| PF/ | ||||||
| PA (pf2) | −0.06 | 0.03 | 0.067 | −0.01 | 0.06 | 0.809 |
| TG (pf1) | 0.14 | 0.03 | <0.001 | −0.01 | 0.05 | 0.819 |
| GS/ | ||||||
| PA (gs3) | −0.05 | 0.04 | 0.212 | −0.12 | 0.06 | 0.032 |
| PF (gs1) | −0.05 | 0.05 | 0.314 | 0.01 | 0.05 | 0.835 |
| IS (gs2) | −0.18 | 0.04 | <0.001 | 0.02 | 0.05 | 0.696 |
| PG/ | ||||||
| PA (pg3) | −0.04 | 0.03 | 0.194 | −0.05 | 0.04 | 0.162 |
| IS (pg1) | −0.56 | 0.03 | <0.001 | −0.67 | 0.03 | <0.001 |
| GS (pg2) | −0.17 | 0.03 | <0.001 | −0.39 | 0.03 | <0.001 |
All continuous variables were normally transformed and adjusted for age, sex, metformin treatment (cohort 2), study centre, total energy intake and carbohydrate, fat and protein intake
See Text box for node and edge abbreviations
Pathway (mediation) effect estimates for the association of physical activity with glycaemic control within the TC-PA model (see Fig. 2)
| Cohort 1 (no diabetes/prediabetes) | Cohort 2 (diabetes) | ||||||
|---|---|---|---|---|---|---|---|
| Outcome node | Edge path | β | β SE | β | β SE | ||
| FG | PA→IS→FG | −0.212 | 0.026 | <0.001 | −0.153 | 0.039 | <0.001 |
| PG | PA→IS→PG | −0.171 | 0.022 | <0.001 | −0.140 | 0.036 | <0.001 |
| FG | PA→IS→GS→FG | 0.015 | 0.004 | <0.001 | |||
| PG | PA→IS→GS→PG | 0.009 | 0.003 | 0.001 | |||
| FG | PA→FI→LF→IS→FG | −0.007 | 0.002 | 0.002 | |||
| PG | PA→FI→LF→IS→PG | −0.006 | 0.002 | 0.002 | |||
| FG | PA→GS→FG | 0.033 | 0.016 | 0.037 | |||
| PG | PA→GS→PG | 0.045 | 0.022 | 0.04 | |||
All continuous variables are normally transformed and adjusted for age, sex, metformin treatment (cohort 2), study centre, total energy intake and carbohydrate, fat and protein intake
See Text box for node abbreviations